Trial design, endpoints, readouts, safety findings, and implications for clinical development.
The clinical pipeline for radiopharmaceuticals is undergoing a radical evolution. While the first wave of commercial success relied heavily on beta-emitting isotopes, researchers and biotech innovators are increasingly pivoting toward…
The clinical pipeline for antibody-drug conjugates and bispecific antibodies is increasingly defined by the pursuit of validated and novel antigens across solid and hematological malignancies. Recent Targeted Oncology Trials have…
The oncology landscape is undergoing a profound transformation driven by the maturation of highly precise biotherapeutics. As conventional chemotherapies are increasingly superseded by therapies offering enhanced tumor specificity, Targeted Oncology…
By early 2026, Chinese biotech innovation has moved from a “fast-follower” role to a primary global engine for first-in-class oncology assets. Chinese firms now drive 70% of the global ADC…
The oncology sector is experiencing a massive leap forward as Bispecific ADCs hit the clinic. While first-generation antibody-drug conjugates proved the viability of targeted chemotherapy, they frequently encountered roadblocks like…
The first generation of obesity drugs faced a critical clinical challenge: nearly 25-40% of the weight lost was comprised of lean muscle and bone mass. In 2026, the focus has…
The 2025–2026 metabolic landscape is defined by a massive shift in patient access: the transition from weekly injections to daily oral small molecules. As of March 2026, the oral GLP-1…
As molecular candidates transition from the laboratory into human testing, artificial intelligence continues to fundamentally reshape the latter half of the biopharma lifecycle. The clinical development and regulatory phases have…